These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 21764277)

  • 21. Profiling the effects of indacaterol on dyspnoea and health status in patients with COPD.
    Jones PW; Mahler DA; Gale R; Owen R; Kramer B
    Respir Med; 2011 Jun; 105(6):892-9. PubMed ID: 21397482
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-effectiveness of tiotropium versus salmeterol: the POET-COPD trial.
    Hoogendoorn M; Al MJ; Beeh KM; Bowles D; Graf von der Schulenburg JM; Lungershausen J; Monz BU; Schmidt H; Vogelmeier C; Rutten-van Mölken MP
    Eur Respir J; 2013 Mar; 41(3):556-64. PubMed ID: 22700844
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Application of latent growth and growth mixture modeling to identify and characterize differential responders to treatment for COPD.
    Stull DE; Wiklund I; Gale R; Capkun-Niggli G; Houghton K; Jones P
    Contemp Clin Trials; 2011 Nov; 32(6):818-28. PubMed ID: 21762787
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-effectiveness of salmeterol, fluticasone, and combination therapy for COPD.
    Oba Y
    Am J Manag Care; 2009 Apr; 15(4):226-32. PubMed ID: 19355795
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-utility analysis of tiotropium versus usual care in patients with COPD in the UK and Belgium.
    Hettle R; Wouters H; Ayres J; Gani R; Kelly S; Lion M; Decramer M
    Respir Med; 2012 Dec; 106(12):1722-33. PubMed ID: 23040833
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Modelling the 5-year cost effectiveness of tiotropium, salmeterol and ipratropium for the treatment of chronic obstructive pulmonary disease in Spain.
    Rutten-van Mölken MP; Oostenbrink JB; Miravitlles M; Monz BU
    Eur J Health Econ; 2007 Jun; 8(2):123-35. PubMed ID: 17370096
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost Effectiveness of the Long-Acting β2-Adrenergic Agonist (LABA)/Long-Acting Muscarinic Antagonist Dual Bronchodilator Indacaterol/Glycopyrronium Versus the LABA/Inhaled Corticosteroid Combination Salmeterol/Fluticasone in Patients with Chronic Obstructive Pulmonary Disease: Analyses Conducted for Canada, France, Italy, and Portugal.
    Reza Maleki-Yazdi M; Molimard M; Keininger DL; Gruenberger JB; Carrasco J; Pitotti C; Sauvage E; Chehab S; Price D
    Appl Health Econ Health Policy; 2016 Oct; 14(5):579-94. PubMed ID: 27516088
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Indacaterol therapy in patients with COPD not receiving other maintenance treatment.
    Decramer M; Rossi A; Lawrence D; McBryan D
    Respir Med; 2012 Dec; 106(12):1706-14. PubMed ID: 23031496
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Indacaterol 75 μg once daily for the treatment of patients with chronic obstructive pulmonary disease: a North American perspective.
    Kerwin EM; Williams J
    Ther Adv Respir Dis; 2013 Feb; 7(1):25-37. PubMed ID: 23296242
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of indacaterol on exercise endurance and lung hyperinflation in COPD.
    O'Donnell DE; Casaburi R; Vincken W; Puente-Maestu L; Swales J; Lawrence D; Kramer B;
    Respir Med; 2011 Jul; 105(7):1030-6. PubMed ID: 21498063
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomised, double-blind comparison.
    Mahler DA; D'Urzo A; Bateman ED; Ozkan SA; White T; Peckitt C; Lassen C; Kramer B;
    Thorax; 2012 Sep; 67(9):781-8. PubMed ID: 22544891
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Roflumilast in combination with long-acting bronchodilators in the management of patients with severe and very severe COPD. A cost-effectiveness analysis for Germany].
    Nowak D; Ehlken B; Kotchie R; Wecht S; Magnussen H
    Dtsch Med Wochenschr; 2013 Jan; 138(4):119-25. PubMed ID: 23322425
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Economic evaluation of tiotropium and salmeterol in the treatment of chronic obstructive pulmonary disease (COPD) in Greece.
    Maniadakis N; Tzanakis N; Fragoulakis V; Hatzikou M; Siafakas N
    Curr Med Res Opin; 2006 Aug; 22(8):1599-607. PubMed ID: 16870084
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Acute effects of indacaterol on lung hyperinflation in moderate COPD: a comparison with tiotropium.
    Rossi A; Centanni S; Cerveri I; Gulotta C; Foresi A; Cazzola M; Brusasco V
    Respir Med; 2012 Jan; 106(1):84-90. PubMed ID: 22035851
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of indacaterol 150 and 300 µg in chronic obstructive pulmonary disease patients from six Asian areas including Japan: a 12-week, placebo-controlled study.
    Kinoshita M; Lee SH; Hang LW; Ichinose M; Hosoe M; Okino N; Prasad N; Kramer B; Fukuchi Y;
    Respirology; 2012 Feb; 17(2):379-89. PubMed ID: 22122202
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sustained 24-hour efficacy of once daily indacaterol (300 μg) in patients with chronic obstructive pulmonary disease: a randomized, crossover study.
    Laforce C; Aumann J; de Teresa Parreño L; Iqbal A; Young D; Owen R; Higgins M; Kramer B;
    Pulm Pharmacol Ther; 2011 Feb; 24(1):162-8. PubMed ID: 20619353
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Assessing efficacy of indacaterol in moderate and severe COPD patients: a 12-week study in an Asian population.
    To Y; Kinoshita M; Lee SH; Hang LW; Ichinose M; Fukuchi Y; Kitawaki T; Okino N; Prasad N; Lawrence D; Kramer B
    Respir Med; 2012 Dec; 106(12):1715-21. PubMed ID: 23040786
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Indacaterol provides 24-hour bronchodilation in COPD: a placebo-controlled blinded comparison with tiotropium.
    Vogelmeier C; Ramos-Barbon D; Jack D; Piggott S; Owen R; Higgins M; Kramer B;
    Respir Res; 2010 Oct; 11(1):135. PubMed ID: 20920365
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bronchodilator efficacy and safety of indacaterol 150 μg once daily in patients with COPD: an analysis of pooled data.
    Bleecker ER; Siler T; Owen R; Kramer B
    Int J Chron Obstruct Pulmon Dis; 2011; 6():431-8. PubMed ID: 22003288
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Indacaterol/Glycopyrronium versus Salmeterol/Fluticasone in Patients with COPD-A Cost-Effectiveness Analysis in the Czech Republic.
    Skoupa J; Kasak V; Klimes J; Valena T
    Value Health Reg Issues; 2018 Sep; 16():112-118. PubMed ID: 30539739
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.